BioCryst, Clearside to Develop Avoralstat for Diabetic Macular Edema

  SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –

– BioCryst to host R&D Day today at 1:00 pm ET –

BioCryst will host a Research and Development (R&D) Day at 1:00 pm ET today at its Discovery Center of Excellence in Birmingham, AL. At the R&D Day, BioCryst plans to describe its drug discovery process and introduce additional therapies from its pipeline. The live webcast and replay of the R&D Day will be available online in the investors section of the BioCryst website at www.biocryst.com.

https://www.globenewswire.com/news-release/2023/11/03/2773333/29446/en/BioCryst-and-Clearside-Biomedical-Enter-Partnership-to-Develop-Avoralstat-for-Diabetic-Macular-Edema-Using-Clearside-s-Proprietary-SCS-Microinjector.html